Drug intelligence / Profile preview

BHV-1490

Development stage: Preclinical
Lead developer: Biohaven

Overview

BHV-1490 is an investigational drug candidate being developed by Biohaven. It is derived from a degrader platform technology licensed from Yale University, which forms the basis of Biohaven's MoDE and TRAP platforms. These platforms are designed to generate extracellular degraders that specifically target and remove disease-causing proteins. While specific indications for BHV-1490 are not detailed, the platform aims to address a range of autoimmune diseases.

Targets

IgM (Immunoglobulin M)ASGPR (Asialoglycoprotein Receptor 1)

Beyond the preview

Go deeper on BHV-1490.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BHV-1490.

Explore the full profile